Telista

Quick links to important sections

Telista

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Telista

Understanding Telista

Telista is an oral medication categorized as an angiotensin II receptor blocker (ARB). It is primarily used to manage chronic conditions related to cardiovascular health and the regulation of blood pressure.

Mechanism of Action

The medication works by interfering with the action of a natural substance in the body called angiotensin II. Angiotensin II is a potent vasoconstrictor, meaning it causes blood vessels to tighten and narrow. By blocking the receptors that this substance binds to, Telista allows the blood vessels to remain more relaxed and dilated.

This process results in several physiological effects:

  • Reduced Peripheral Resistance: As blood vessels widen, the heart does not have to exert as much force to circulate blood throughout the body.
  • Lowered Blood Pressure: The relaxation of the vascular system leads to a decrease in systemic blood pressure levels.
  • Improved Blood Flow: Enhanced vessel dilation facilitates smoother circulation to vital organs.

Primary Uses

Telista is commonly prescribed for the long-term management of essential hypertension (high blood pressure). Maintaining blood pressure within a standard range is a critical component of cardiovascular care, as persistent hypertension can place undue stress on the heart and arteries.

In addition to treating hypertension, this medication may be utilized to reduce the risk of cardiovascular events, such as strokes or heart attacks, in individuals who are at high risk due to underlying vascular disease or other systemic health factors.

What side effects are possible with Telista?

Possible side effects and safety information

Telista’s official safety profile is formally documented by regulatory authorities, classifying potential adverse reactions by frequency and the body system affected.

Classification Examples of Officially Listed Adverse Reactions
Common (Affects ge1 in 100 users) Back pain, upper respiratory tract infections (including sinusitis), and diarrhea.
Uncommon (Affects 1 to 10 in 1,000 users) Anemia, hyperkalemia (high potassium levels), depression, vertigo, hypotension (low blood pressure), and renal impairment.
Rare (Affects 1 to 10 in 10,000 users) Sepsis (including fatal outcome), anaphylactic reaction, angioedema (swelling of the face, throat, or tongue), and tendon pain.

Serious adverse outcomes explicitly highlighted in regulatory documents include the risk of Fetal Toxicity, which is a primary concern for use during pregnancy, and the potential for Acute Renal Failure.

Safety notes for specific populations and conditions are mandated in official labeling:

  • Pregnancy: Telista is contraindicated during the second and third trimesters, due to the risk of injury and death to the developing fetus, and is not recommended during the first trimester.
  • Severe Hepatic Impairment: The medication is contraindicated in patients with severe liver impairment, cholestasis, or biliary obstructive disorders.
  • Dual RAAS Blockade: The combination of Telmisartan with certain other blood pressure medicines (e.g., Aliskiren) is generally avoided in patients with diabetes or moderate-to-severe renal impairment due to the increased risk of hypotension, hyperkalemia, and worsening renal function.

The regulatory safety structure delineates the potential risks across multiple physiological systems, defining the strict parameters under which the medicine is authorized for use.

Overdose and Emergency Response

Overdose and When to Seek Help

The primary manifestation of Telista overdose documented in regulatory labeling is profound hypotension (severe drop in blood pressure), which may lead to associated signs such as dizziness and fainting (syncope). Other clinical findings include changes in heart rate, such as tachycardia or bradycardia. Physiologically, overdose may be associated with signs of acute stress on the renal system, evidenced by increased serum creatinine and potential for acute renal failure.

Required Emergency Actions

Immediate emergency assistance must be sought if the individual exhibits severe signs, including collapse, having a seizure, experiencing trouble breathing, or being unable to be awakened. For any suspected overdose, professional medical help should be contacted immediately.

Management and Monitoring

Official regulatory documents state that treatment for Telmisartan overdose is symptomatic and supportive. The patient must be closely monitored. If severe hypotension occurs, a specific procedural step is to place the patient in the supine position and administer an intravenous infusion of normal saline for volume replacement.

No specific antidote is known for Telmisartan, and the drug is not removed by haemodialysis. Furthermore, frequent monitoring of serum electrolytes and creatinine is mandated to track the physiological status during recovery.

This profile establishes specific, label-derived conditions that require immediate emergency medical assistance, as described by government health authorities.

Therapeutic Uses of Telista

What Telista treats: main uses and benefits

Telista (Telmisartan) is primarily used for the long-term management of chronic conditions that pose a risk to cardiovascular health, aiming to reduce the likelihood of future serious events. The central focus is on conditions that are often asymptomatic but require sustained medical intervention. It is used for the treatment of essential hypertension and for the reduction of cardiovascular morbidity in high-risk adults.

Telista is commonly used in conditions characterized by persistent elevated blood pressure, and is applied in clinical settings marked by high cardiovascular risk markers, and for indicators of diabetic kidney stress.

“The medication is generally considered relevant in contexts involving heightened systemic burden where long-term vascular support is needed.”

The key therapeutic benefit is sustained blood pressure control, which supports overall vascular health and may assist in easing the systemic strain on the cardiovascular system. For high-risk individuals, this provides protective therapeutic support that contributes to lowering the long-term probability of major cardiovascular episodes. Furthermore, the medication is relevant for easing symptomatic burden by helping to assist in managing the progression of kidney changes and supports renal function in Type 2 diabetes patients.


Quick Fact: Relief for Persistent Elevated Blood Pressure

Regulatory References

  1. European Medicines Agency overview

Eligibility and Restrictions for Use

The eligibility profile for Telista (Telmisartan) is defined by mandatory regulatory constraints and is primarily restricted to specified adult populations. Use is determined by age, underlying organ function, and specific co-administered medications.

Populations Who Must Not Use Telista (Contraindicated)

Telmisartan is contraindicated and must not be used by several groups due to explicit regulatory prohibition:

  • Pregnant Women: Use is prohibited during the second and third trimesters due to the high risk of fetal injury and death.
  • Hepatic Impairment: Patients with severe hepatic impairment, cholestasis, or biliary obstructive disorders.
  • Drug-Specific: Patients with Diabetes Mellitus who are simultaneously taking Aliskiren.
  • Hypersensitivity: Individuals with known hypersensitivity to the active substance or any product component.

Populations with Restrictions or Limitations

  • Pediatric Use: Safety and efficacy have not been established in children and adolescents under 18 years; use is not recommended.
  • Lactation: Use is not recommended for nursing mothers.
  • Organ Function: Patients with mild to moderate hepatic impairment or any renal impairment require special monitoring. Patients with volume or salt depletion must have this condition corrected before treatment initiation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Telmisartan (Telista) is defined by its action on the Renin-Angiotensin System (RAS) and its impact on the clearance of certain co-administered drugs.

Formal Regulatory Restrictions

  • Aliskiren: Co-administration is contraindicated in patients diagnosed with diabetes mellitus or with moderate-to-severe renal impairment. This restriction is mandated due to the severe risks associated with dual blockade of the RAS, including hyperkalemia and acute renal failure.
  • Severe Hepatic Impairment: Telmisartan is also formally contraindicated in cases of severe hepatic impairment or biliary obstructive disorders, as reduced hepatic clearance significantly increases Telmisartan's systemic exposure.

Clinically Significant Interactions

  • Digoxin and Lithium: Concomitant use with Telmisartan has been officially documented to increase the plasma concentrations of Digoxin and Lithium, which requires mandated monitoring of serum levels when initiating or adjusting therapy.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Co-administration may lead to a reduction of the intended antihypertensive effect of Telmisartan. This combination also elevates the risk of deterioration of renal function.
  • Potassium-Elevating Agents: Combining with substances like Potassium-sparing Diuretics or Potassium Supplements carries a heightened risk of hyperkalemia (high serum potassium) due to additive effects on potassium retention.
  • Metabolic Profile: Telmisartan is not metabolized by the cytochrome P450 system; therefore, clinically significant pharmacokinetic interactions with inhibitors or inducers of these enzymes are not expected.

Mechanism of Action

Targeting the AT1 Receptor

Telista is a selective competitive antagonist that primarily acts on the Angiotensin II type 1 ( AT1) receptors. Its fundamental action is to occupy and block these receptors, preventing the natural signaling molecule, angiotensin II, from binding and initiating its response. This molecular interaction affects the activity of the Renin-Angiotensin-Aldosterone System (RAAS) pathway.


Modulating Vascular Resistance

By binding to the AT1 receptor, Telista interferes with the signals that cause the smooth muscle in blood vessel walls to contract. This inhibition results in the relaxation and widening of the peripheral arteries, thereby reducing the total resistance encountered by the blood flow and influencing systemic arterial pressure.


Influencing Fluid Balance

The drug's mechanism also contributes to modulating the body's fluid volume by indirectly interfering with the signal for aldosterone release. This action alters the signaling related to fluid retention in the kidney, resulting in a mild decrease in circulating fluid volume and an adjustment of the pressure exerted on blood vessel walls.

Dosage and Administration Information

Telista (telmisartan) is an angiotensin II receptor blocker (ARB). It is generally prescribed once daily to manage high blood pressure (hypertension) and reduce the risk of cardiovascular events like stroke and heart attack.

Administration and Dosage

Instruction Detail
Timing Take one tablet daily at the same time each day to maintain a constant level of the medicine in your blood.
Food Intake May be taken with or without food.
How to Take Swallow the tablet whole with a glass of water. Do not chew, crush, or break the tablet. Tablets should be removed from the blister pack immediately before administration.
Missed Dose If you miss a dose, take it as soon as you remember, unless it is almost time for your next scheduled dose. If so, skip the missed dose and continue with your regular schedule. Do not take a double dose.
Duration Do not stop taking Telista without consulting your prescribing healthcare provider, even if you feel well. Controlling blood pressure is a long-term treatment, and abrupt discontinuation can increase blood pressure.

Important Considerations

The full blood pressure-lowering effect may take four weeks of consistent use to be reached. Your physician may adjust the dosage, typically starting at 40 mg once daily, with a usual maintenance range between 20 mg and 80 mg once daily.

Patients with liver impairment or those who are volume-depleted (e.g., due to diuretic therapy) may require closer monitoring or a lower initial dose. Telmisartan is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal harm. You should inform your doctor immediately if you become pregnant while on this medication.

Recent Clinical Evidence

Research evidence / Overview of Studies for Telista (Telmisartan)

This overview summarizes the formal research landscape for Telmisartan, describing the types of studies conducted and the outcomes they explored, without offering clinical advice or making guarantees about personal health outcomes. Research does not determine whether an individual will respond similarly; findings describe group patterns, not personal outcomes.


Evidence for Use in Essential Hypertension

The study of Telmisartan's role in Persistent Elevated Blood Pressure (hypertension) was studied for defined time intervals in multiple Randomized Controlled Trials (RCTs). These research trials monitored key outcomes monitoring physiological strain or stress and used Ambulatory Blood Pressure Monitoring (ABPM). Findings describe patterns observed in these studies, including the degree to which blood pressure measurements changed over the study period. Follow-up durations were limited to a few months, and this evidence is limited in providing direct, long-term data on definitive major clinical outcomes for patients whose only condition is uncomplicated hypertension.


Evidence for Use in Cardiovascular Risk Reduction

Telmisartan was evaluated in Extended-duration Randomized Controlled Trials (RCTs) specifically designed to track major health events over several years in high-risk adults (ge 55 years) with vascular disease or Type 2 diabetes. The primary outcomes tracked were related to major cardiovascular episodes (e.g., stroke, heart attack). In trials comparing Telmisartan to an active comparator (an ACE inhibitor), the studies reported that the frequency of the primary composite outcome was not statistically different between the two treatments. Data related to the primary composite outcome were not statistically distinct from placebo in high-risk patients who were intolerant to other medications, leaving research uncertainty in that subgroup.


Research in the Context of Type 2 Diabetes and Kidney Stress

Studies explored temporary physiological imbalance related to the kidneys in patients with Type 2 Diabetes Mellitus. Subgroup analyses tracked outcomes such as albuminuria (an outcome linked to inflammatory states). Studies observed patterns where the progression of albuminuria was reported to be less frequent than in the placebo group. However, data on the most severe kidney outcomes, like the need for dialysis, is based on very low event counts, meaning certainty remains low for those specific endpoints. Furthermore, comparative evidence is lacking for many non-cardiovascular outcomes against a broad range of alternative treatments.

Key Studies & References

  1. Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) - Cardiovascular outcomes

Frequently Asked Questions (FAQ)

Common questions about Telista (FAQ)


Q: How quickly does Telista start working after the first dose?

According to regulatory information, the onset of antihypertensive activity (when blood pressure lowering begins) occurs approximately three hours after a single oral dose. However, official documents indicate that the full blood pressure-lowering effect of the medication may take up to four weeks of consistent daily use to be reached.


Q: Does Telista affect blood sugar levels or diabetes control?

The official label notes that Telista is contraindicated (meaning it must not be used) in patients with diabetes mellitus who are simultaneously taking the medication Aliskiren. Studies of Telista in combination with other medicines have also reported changes in blood sugar levels (hyperglycemia) as a possible effect.


Q: Does Telista interact with common over-the-counter pain relievers?

Regulatory documents explicitly warn about a significant interaction with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen or naproxen. This combination may reduce Telista’s effectiveness in lowering blood pressure and elevate the risk of worsening kidney function. Regulatory warnings focus on the known interaction with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).


Q: What happens if I accidentally miss a dose of Telista?

Telista has a long duration of action (a terminal elimination half-life of approximately 24 hours), meaning its blood pressure-lowering effect is designed to last for the full daily interval. Official instructions describe what to do if a dose is missed, which is to proceed with the next scheduled dose as planned.


Q: Is it normal to feel a bit lightheaded when starting Telista?

Dizziness and lightheadedness are listed as possible side effects in official safety documents. These sensations are commonly reported in official safety documents and are linked to the drug's intended action.


Q: Does Telista affect heart rate or rhythm?

Official safety documents list several effects on heart function. Uncommon reported adverse reactions include palpitation (a feeling of the heart beating too hard or fast), tachycardia (a fast heart rate), and bradycardia (a slow heart rate).


Q: What happens if I take too much Telista?

Symptoms of an overdose may include dizziness, fainting, and an unusually fast or slow heartbeat. Regulatory guidelines emphasize the importance of seeking professional assistance in the event of an overdose.


Q: Is there a specific time of day that Telista should be taken?

Official instructions state to take the tablet once daily at the same time each day to maintain consistent levels of the medication in the blood. However, the regulatory documents do not mandate a specific time of day (such as morning versus evening) for administration.


Q: Why does my prescription bottle for Telista have a specific warning label?

Regulatory bodies require certain critical risks to be clearly highlighted. Common warnings include the risk of fetal toxicity (prohibiting use during the last six months of pregnancy), as well as risks associated with impaired liver or kidney function and the potential for hyperkalemia (high potassium) due to specific drug interactions.


Q: Is Telista the same as [other common drug name]?

Telista belongs to the Angiotensin II Receptor Blocker (ARB) class of medications. Official information describes Telista as belonging to the Angiotensin II Receptor Blocker (ARB) class, which has a distinct mechanism of action compared to other types of blood pressure medications.


Q: Does Telista cause weight gain or weight loss?

According to official adverse event reports, weight gain has been listed as an adverse event of unknown incidence. Weight loss is not specifically or frequently noted in official documents as a reported side effect.


Q: Can Telista cause problems with sleep or insomnia?

Insomnia (difficulty sleeping) is listed in official safety documents as a common side effect. This means it has been reported in at least 1 out of every 100 users.


Q: Are there any major diet restrictions when taking Telista?

Due to the drug’s potential to increase potassium levels in the blood (hyperkalemia), official instructions strongly advise patients to avoid potassium-containing salt substitutes or over-the-counter potassium supplements unless specifically directed by a healthcare provider.


Q: Can I drink coffee or caffeine while on Telista?

While there is no major regulatory contraindication against consuming caffeine, the product monograph notes that Telmisartan has a minor interaction with caffeine. This minor interaction is typically not a contraindication, but consistency in usage of any product is important for managing blood pressure.


Q: Is it okay to take Telista with supplements like fish oil or magnesium?

Official labeling specifically warns against potassium supplements due to interaction risks. There is no consistent warning or contraindication found across major regulatory documents for supplements such as Fish Oil or Magnesium.


Q: Are there different strengths or doses of Telista available?

Yes, official product information indicates that the tablets are manufactured and available in multiple dosage strengths, which typically include 20 mg, 40 mg, and 80 mg.


Q: Is there a generic version of Telista available?

Yes. The active ingredient in Telista is telmisartan, which is now available as a generic medication. It is supplied by multiple manufacturers under various generic and brand names internationally.


Q: Does Telista make you feel tired or dizzy?

Official safety information lists dizziness and headache as common side effects. Additionally, fatigue and general tiredness or weakness are also commonly reported adverse events.


Q: Does Telista affect fertility in men or women?

Non-clinical studies, which use animal models for initial safety screening, showed no effect on mating performance, reproductive organs, or fertility in either sex at the tested doses. Major warnings regarding effects on human fertility are not listed in the official product information.


Q: Are headaches a common side effect of Telista?

Yes, official safety documents list headache as a common side effect. Common means it is expected to affect at least 1 out of every 100 people who use the medication.


Q: Does Telista cause skin rashes or sensitivity to the sun?

Rash and pruritus (itching) are listed in official safety documents as reported side effects. Official information indicates that precautions regarding exposure to direct sunlight may be warranted due to the possibility of photosensitive skin reactions.


Q: Why do some people say Telista makes them cough?

Coughing is listed in official safety documents as a common side effect. Clinical studies have examined the occurrence of cough with Telista compared to other treatments.


Q: Can Telista be purchased over-the-counter in some countries?

No. In major international markets, Telista is strictly classified as an oral prescription medication and is available only with a doctor's prescription.


Q: Is it true that Telista can cause swelling in the legs or ankles?

Peripheral edema (swelling in the hands, lower legs, and feet) is listed as an uncommon side effect in some official safety documents. Uncommon means it may affect 1 to 10 out of every 1,000 users.


Q: What are the most common mild side effects reported for Telista?

The officially listed common side effects, which affect at least 1 in 100 users, include back pain, upper respiratory tract infections (such as sinusitis), and diarrhea.


Q: What happens if Telista expires, is it still okay to take?

Official instructions advise against taking expired medication. The regulatory disposal instructions state that unused or expired tablets should be disposed of through an official drug take-back program or specific household waste procedures.


Q: Are there any vitamins or foods that should be avoided with Telista?

Patients are strongly advised to avoid potassium-containing salt substitutes or over-the-counter potassium supplements. This is a necessary precaution to manage the potential for high potassium levels (hyperkalemia) in the blood.

How should Telista be stored and disposed of?

Storage and Protection Requirements

Telmisartan tablets must be stored at a defined Controlled Room Temperature, typically 20°C to 25°C (68°F to 77°F). The official labeling mandates that the product be protected from excessive moisture and light to maintain stability, as the tablets are hygroscopic. The medicine must remain sealed in its original blister pack until immediately before administration.

Child Safety and Disposal

All medication, including Telista, must be stored out of the sight and reach of children for safety. Disposal of unused or expired tablets should be conducted through an official drug take-back program. If a take-back option is unavailable, the tablets should be mixed with an undesirable substance (such as used coffee grounds) and sealed in a container before being placed in household trash. The tablets must not be disposed of by flushing down the toilet or by allowing the product to enter water systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Telista found in:

A-Z Index: